Aviceda Therapeutics: Funding, Investors & Team (Oct 2026)
Aviceda Therapeutics is a biotech company in the late stages of pre-clinical development that is focused on creating drugs to treat glyco-immune diseases. Their approach involves utilizing the field of glycobiology to target the innate immune system and chronic inflammation in a precise and powerful manner. They leverage advanced technologies and in-depth biological understanding to develop innovative products. Aviceda's high-throughput screening platform is used to quickly identify and refine ligands with high affinity and specificity for various types of innate immune cells. The company's product pipeline includes treatments for eye diseases, fibrosis, neurology, and oncology, such as AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 for oncology, neurology, and fibrosis.
Aviceda Therapeutics has raised $223M across 2 funding rounds on record, the most recent a Series C of $208M announced in Jan 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aviceda Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Aviceda Therapeutics Funding Rounds
Aviceda Therapeutics raised $15.6M in an undisclosed round announced in May 2023.
1.7 years later, a Series C of $208M was announced in Jan 2025.
Aviceda Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Aviceda Therapeutics Funding Compared to Other Biotechnology Startups
Aviceda Therapeutics' latest round of $208M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aviceda Therapeutics in Biotechnology and Cambridge
Companies Similar to Aviceda Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Aviceda Therapeutics Funding FAQs
What does Aviceda Therapeutics do?
Aviceda Therapeutics is a biotech company in the late stages of pre-clinical development that is focused on creating drugs to treat glyco-immune diseases. Their approach involves utilizing the field of glycobiology to target the innate immune system and chronic inflammation in a precise and powerful manner. They leverage advanced technologies and in-depth biological understanding to develop innovative products. Aviceda's high-throughput screening platform is used to quickly identify and refine ligands with high affinity and specificity for various types of innate immune cells. The company's product pipeline includes treatments for eye diseases, fibrosis, neurology, and oncology, such as AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 for oncology, neurology, and fibrosis.
How much funding has Aviceda Therapeutics raised?
Aviceda Therapeutics has raised $223M across 2 rounds on record. The most recent is a Series C of $208M announced in Jan 2025.
When did Aviceda Therapeutics last raise funding?
Aviceda Therapeutics' most recent funding round on record is a Series C of $208M, announced in Jan 2025.
Who founded Aviceda Therapeutics?
FundedIQ lists Christopher Scott (Founder), Michael Tolentino (Founder) at Aviceda Therapeutics.
Where is Aviceda Therapeutics headquartered?
Aviceda Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Aviceda Therapeutics have?
Aviceda Therapeutics is in the 51-100 employee band.
How does Aviceda Therapeutics' funding compare to other Biotechnology startups?
Aviceda Therapeutics' latest round of $208M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Aviceda Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aviceda Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.